Skin Cancer Treatment — Evidence-Based Clinical Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Skin cancer is the most common malignancy in fair-skinned populations, with over 5 million new cases of non-melanoma skin cancer (NMSC) and approximately 325,000 new cases of melanoma diagnosed globally each year. Cumulative ultraviolet radiation exposure — both from natural sunlight (UVB 290–320 nm) and artificial tanning devices — is the dominant aetiological factor, inducing characteristic C→T and CC→TT pyrimidine dimer mutations in tumour suppressor genes including TP53, CDKN2A and the Hedgehog signalling pathway gene PTCH1.

The major categories of skin malignancy are:

• Basal cell carcinoma (BCC): Arises from basal keratinocytes. Locally destructive but very rarely metastatic (<0.1%). Over 90% driven by Hedgehog pathway activation (PTCH1 mutation). Accounts for ~80% of NMSCs.
• Squamous cell carcinoma (SCC): Arises from suprabasal keratinocytes. Risk of regional lymph node metastasis 2–5%; high-risk features elevate this to 10–30%. UV-induced TP53 mutations are cardinal. Precursor: actinic keratosis (AK).
• Melanoma: Arises from melanocytes. Relatively uncommon but responsible for ~75% of skin cancer deaths. BRAF V600E/K mutations in ~50% of cutaneous melanoma. AJCC 8th edition staging based on Breslow thickness, ulceration, mitotic rate and nodal status determines prognosis and treatment.
• Merkel cell carcinoma (MCC): Rare, highly aggressive neuroendocrine carcinoma; frequently associated with Merkel cell polyomavirus (MCPyV) and UV exposure.
• Rare tumours: Dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma, adnexal carcinomas, sebaceous carcinoma.

Early detection through skin self-examination, dermoscopy-assisted clinical examination and total body photography significantly improves outcomes across all skin cancer types.

Skin cancer treatment encompasses all primary and metastatic cutaneous malignancies:

• Basal cell carcinoma (BCC) subtypes: Nodular (most common), superficial (particularly amenable to topical therapies), morphoeic/sclerosing (infiltrative, requires wider margins), basosquamous (higher metastatic risk), perineural (requires wider clearance and consideration of adjuvant radiotherapy). Locally advanced and metastatic BCC is now treated with Hedgehog pathway inhibitors.
• Cutaneous squamous cell carcinoma (cSCC) and CSCC: Includes in-situ (Bowen disease/SCC is) and invasive tumours. High-risk features per the Brigham and Women Hospital (BWH) staging include tumour diameter >2 cm, depth >6 mm or beyond subcutaneous fat, perineural invasion, poorly differentiated histology, tumour location on temple/ear, and immunosuppression (organ transplant recipients face 65–250× increased SCC risk).
• Actinic keratoses (AK): Premalignant intraepidermal lesions; risk of progression to invasive SCC approximately 8% over 10 years per lesion. Managed by field treatment (5-FU, imiquimod, ingenol mebutate, PDT) or lesion-directed cryotherapy.
• Melanoma (all stages): Stages I–IV per AJCC 8th edition; in-situ (stage 0), localised (I–II), regional nodal (III), distant metastatic (IV). Lentigo maligna melanoma on chronically sun-damaged skin requires wide margins or staged excision.
• Merkel cell carcinoma: Management requires multidisciplinary team (dermatology, oncology, radiation oncology, surgery); PD-L1 immunotherapy has transformed outcomes in advanced disease.
• DFSP: Locally aggressive, rarely metastatic fibroblastic tumour driven by COL1A1-PDGFB fusion gene — targetable with imatinib (tyrosine kinase inhibitor).
• Malignant fibrous histiocytoma (MFH) / undifferentiated pleomorphic sarcoma: Rare, requires wide surgical excision and multidisciplinary sarcoma team input.

Treatment selection depends on tumour type, stage, anatomical location, patient performance status, molecular profile and patient preference:

• Surgery (Mohs/WLE): Suitable for the majority of localised BCC, SCC and melanoma. Mohs micrographic surgery is particularly indicated for tumours on the face, ears, scalp, hands and feet (H-zone); tumours with aggressive histological subtypes; recurrent tumours; and lesions in sites where maximal tissue conservation is critical (eyelids, lips, nasal ala).
• Sentinel lymph node (SLN) biopsy: Recommended for melanoma with Breslow thickness >0.8 mm, or >0.8 mm with ulceration or mitotic rate ≥1/mm². The MSLT-1 randomised trial established SLN biopsy as the standard staging procedure, with 10-year melanoma-specific survival benefit in SLN-positive patients who received completion lymph node dissection (CLND) or nodal observation.
• Adjuvant systemic therapy — melanoma: Patients with resected stage III melanoma are eligible for pembrolizumab (KEYNOTE-716 — significantly improved recurrence-free survival) or, if BRAF V600E/K-mutant, dabrafenib plus trametinib (COMBI-AD — 5-year relapse-free survival 52% vs 36% placebo). Molecular testing (BRAF V600E/K by PCR or next-generation sequencing) is essential before adjuvant therapy.
• Hedgehog pathway inhibitors (advanced BCC): Patients with locally advanced BCC not amenable to surgery or radiotherapy, or metastatic BCC. Confirmed by tumour histology; no specific biomarker test required as PTCH1 pathway activation is near-universal.
• PD-1/PD-L1 inhibitors (advanced cSCC, MCC, melanoma): No mandatory PD-L1 testing required for cSCC (cemiplimab) or MCC (avelumab) eligibility; ECOG performance status ≤2; no active autoimmune disease requiring systemic immunosuppression; adequate organ function.
• DFSP — imatinib: Unresectable or recurrent/metastatic DFSP; COL1A1-PDGFB fusion confirmed by FISH or RT-PCR.

Treatment is stratified by tumour type, stage and anatomical considerations. A multidisciplinary team approach is recommended for all non-superficial or high-risk tumours:

Basal Cell Carcinoma (BCC):

• Mohs micrographic surgery: 5-year cure rate 99%+ for primary BCC; 94% for recurrent BCC. Staged excision with immediate margin control using horizontal frozen sections. First-line for H-zone, aggressive histology, recurrent, large or incompletely excised tumours.
• Wide local excision: 4 mm margins for well-defined, low-risk (<2 cm) BCC; 5–10 mm for morphoeic or poorly defined tumours.
• Curettage and electrodesiccation (C&E): For low-risk, well-defined nodular or superficial BCC on non-terminal hair-bearing skin; not appropriate for H-zone or morphoeic subtypes.
• Topical therapy (superficial BCC only): Imiquimod 5% cream (3× weekly for 6 weeks) — ~80% histological clearance; 5-fluorouracil (5-FU) cream twice daily for 6 weeks — comparable efficacy.
• Vismodegib (Erivedge) / Sonidegib (Odomzo): Smoothened (SMO) inhibitors targeting the Hedgehog pathway. STEVIE trial (vismodegib): 68.5% ORR in locally advanced BCC, 33.3% ORR in metastatic BCC. Used for locally advanced or metastatic BCC; common side effects include muscle cramps, alopecia and dysgeusia.

Cutaneous Squamous Cell Carcinoma (cSCC):

• Mohs micrographic surgery or wide local excision with 4–6 mm margins (low-risk) or 6–10 mm (high-risk features)
• SLN biopsy considered for T3 or T4 tumours (BWH staging), perineural invasion or significant immunosuppression
• Adjuvant radiotherapy for positive/close margins or extensive perineural invasion where re-excision is not feasible
• Cemiplimab (Libtayo): Anti-PD-1 antibody — EMPOWER-CSCC-1: 47.2% ORR in metastatic/locally advanced cSCC; first-line for patients not amenable to curative surgery or radiation. Pembrolizumab also approved for advanced cSCC.

Melanoma:

• Wide local excision — margin by Breslow: in-situ 5 mm; ≤1.0 mm 1 cm; 1.01–2.0 mm 1–2 cm; >2.0 mm 2 cm
• SLN biopsy (MSLT-1 trial) for staging of tumours >0.8 mm
• Adjuvant: pembrolizumab (KEYNOTE-716, stage IIB/IIC/III), nivolumab (CheckMate 238), dabrafenib + trametinib (COMBI-AD, stage III BRAF-mutant)
• Metastatic: combination immunotherapy ipilimumab + nivolumab (CheckMate 067 — 5-year OS 52%); BRAF+MEK inhibitors dabrafenib + trametinib or vemurafenib + cobimetinib for BRAF-mutant

Merkel Cell Carcinoma: Surgery + adjuvant radiotherapy for localised disease; avelumab (JAVELIN Merkel 200, 33% ORR) or pembrolizumab for metastatic disease.

DFSP: Wide excision (2–3 cm margins) or Mohs surgery; imatinib 400–800 mg/day for unresectable/metastatic disease — ~70% response rate.

Evidence-based skin cancer treatment delivers high cure rates for early-stage disease and meaningful survival extension for advanced stages:

• Exceptional cure rates for localised disease: Mohs surgery achieves 5-year cure rates of 99%+ for primary BCC and >95% for primary cSCC at low-risk sites. Standard wide excision of thin melanoma (Breslow <1 mm, no ulceration) is associated with 10-year melanoma-specific survival exceeding 95%.
• Tissue conservation with Mohs: Unlike standard excision with preset margins, Mohs surgery maps 100% of the peripheral and deep margins, enabling conservation of maximum healthy tissue — critical for functional and cosmetic outcomes on the face, eyelids, nose, lips and ears.
• Durable immunotherapy responses in advanced melanoma: Combination ipilimumab + nivolumab (CheckMate 067) demonstrated 5-year overall survival of 52% in previously untreated metastatic melanoma — a dramatic improvement from the historical median survival of 6–12 months with chemotherapy. Long-term responders appear to achieve functional cure in a meaningful proportion.
• Adjuvant therapy reducing relapse: Pembrolizumab (KEYNOTE-716) and dabrafenib + trametinib (COMBI-AD) reduce distant recurrence and improve relapse-free survival in stage II–III resected melanoma by approximately 30–40% relative risk reduction.
• Transformation of MCC outcomes: Avelumab and pembrolizumab have converted metastatic MCC — previously associated with median survival of 4–6 months with chemotherapy — into a condition where durable responses exceeding 5 years are documented in approximately 15–20% of treated patients.
• Disease control without surgery in advanced BCC: Vismodegib allows disease control in patients with basal cell naevus syndrome (Gorlin syndrome) or in elderly patients with multiple BCCs, avoiding repeated surgical procedures.

Each treatment modality carries a distinct safety profile that must be weighed against disease severity and patient comorbidities:

• Surgical risks: Wound infection (1–5%), dehiscence, haematoma, seroma, peripheral nerve injury producing numbness or weakness, scar hypertrophy or keloid formation, ectropion (periocular surgery), graft/flap failure. General anaesthesia risks for larger resections in elderly patients.
• Radiotherapy: Acute radiodermatitis (erythema, moist desquamation); chronic: telangiectasia, skin atrophy, radiation-induced fibrosis, secondary malignancy risk (especially in patients with Gorlin syndrome or xeroderma pigmentosum). Not appropriate for tumours overlying cartilage or bone.
• Hedgehog pathway inhibitors (vismodegib/sonidegib): Muscle cramps (72%), alopecia (64%), dysgeusia/ageusia (55%), weight loss, fatigue, nausea. Highly teratogenic — absolute contraindication in pregnancy; stringent contraception required. Discontinuation rates due to AEs are high (~50% in long-term use).
• Immune checkpoint inhibitors: Immune-related adverse events (irAEs) affecting any organ system. Key irAEs: immune-related colitis (diarrhoea, cramping — 12–22% grade 1–2, <2% grade 3–4), pneumonitis (3–5%), hepatitis (transaminase elevation), endocrinopathies (thyroiditis, hypophysitis, adrenal insufficiency — may be permanent requiring hormone replacement), dermatitis, nephritis, uveitis. Combination ipilimumab + nivolumab carries higher irAE rates (59% grade 3–4) than monotherapy. Management: hold drug, systemic corticosteroids (prednisolone 1–2 mg/kg), specialist involvement.
• BRAF/MEK inhibitors: Pyrexia (60–70%), fatigue, rash, photosensitivity, nausea, secondary cutaneous SCC and keratoacanthoma (paradoxical MAPK activation in BRAF wild-type cells — managed by excision), QTc prolongation. Ophthalmological monitoring for serous retinopathy.
• Imatinib (DFSP): Periorbital oedema, nausea, muscle cramps, fatigue, myelosuppression; hepatotoxicity — regular LFT monitoring required.

Post-treatment surveillance is essential for detecting recurrence, second primaries and treatment-related toxicities:

• BCC surveillance: 3-year risk of new BCC after first diagnosis is approximately 35–50%. Follow-up: 6-monthly skin examination for 2 years then annually; patient skin self-examination education; sun protection counselling and UV avoidance.
• cSCC surveillance: High-risk cSCC: 3-monthly examination for 2 years, 6-monthly for 2 further years, then annually. Lymph node palpation at each visit. Regional ultrasound ± FDG-PET/CT for high-risk tumours at 6 and 12 months. Immunosuppressed patients require more frequent surveillance.
• Melanoma surveillance: Stage I: 6-monthly for 5 years then annually. Stage II–III: 3–4 monthly for first 2 years, 6-monthly to 5 years, then annually. Total body photography and sequential dermoscopy. PET-CT or CT chest/abdomen/pelvis for stage III–IV. Serum LDH for stage IV. Brain MRI for stage IV (annual or symptom-driven for stage III).
• Immunotherapy monitoring: Regular LFTs, TFTs (thyroid function every 6–8 weeks), morning cortisol, full blood count. Symptom-based investigation for colitis, pneumonitis and nephritis. irAEs can emerge months to years after cessation of therapy.
• BRAF/MEK inhibitor monitoring: Ophthalmological assessment every 3 months (serous retinopathy); dermatological surveillance for secondary SCC; echocardiography and ECG if cardiac risk present; LFTs every 2–4 weeks.
• Dermoscopy and total body photography: Used in high-risk patients (multiple atypical naevi, personal or family history of melanoma) to detect changing lesions at an early stage.

Skin cancer treatment costs vary substantially by tumour type, stage, treatment modality and healthcare system:

• Mohs micrographic surgery: USD $2,000–5,000 for a primary lesion in the US; cost rises with number of stages required. Significantly lower in India ($500–1,500) and Southeast Asia.
• Wide local excision: USD $1,000–3,000 as an outpatient procedure; higher if general anaesthesia, complex flap or graft reconstruction required.
• Radiotherapy (curative or adjuvant): USD $10,000–30,000 for a full course in the US; available at lower cost in national health systems and Indian cancer centres.
• Immune checkpoint inhibitors: Pembrolizumab, nivolumab and cemiplimab cost approximately $150,000–200,000 USD/year at US list price. Combination ipilimumab + nivolumab can exceed $300,000/year. Biosimilar development and generic access in India and other middle-income countries substantially reduces cost — pembrolizumab biosimilars are available in India at approximately 20–30% of the US list price through IQVIA-listed programs.
• BRAF/MEK inhibitors: Dabrafenib + trametinib combination approximately $200,000–250,000 USD/year; generic formulations available in some countries.
• Vismodegib: Approximately $9,000–15,000 USD/month; patient assistance programs available through Genentech (US); European pricing varies by country.
• Molecular testing: BRAF V600 mutation testing by PCR/NGS adds $300–1,500; PD-L1 immunohistochemistry $200–500; comprehensive tumour mutational burden and MSI testing by NGS panel $2,000–5,000.
• Medical tourism: India, Thailand and Turkey offer complete melanoma staging workup, surgery and access to approved immunotherapy at 30–60% of US/UK private rates, with internationally accredited oncology centres managing all skin cancer types.

While surgery and approved systemic therapies form the backbone of evidence-based skin cancer treatment, several alternative and complementary approaches have defined roles in specific contexts:

• Photodynamic therapy (PDT): Topical photosensitiser (5-aminolevulinic acid, methylaminolevulinate) activated by red or blue light. Highly effective for superficial BCC (complete response ~87%), Bowen disease/SCC is, and actinic keratoses (field treatment). Not suitable for invasive SCC or melanoma. Excellent cosmetic outcome. Side effects: pain during illumination, transient erythema and crusting.
• Intralesional therapies: Intralesional 5-FU, bleomycin or methotrexate for unresectable superficial lesions in patients unfit for surgery. Rose Bengal (PV-10) intralesional for melanoma in-transit metastases (investigational).
• Electrochemotherapy: Reversible electroporation + bleomycin; approved in Europe for unresectable cutaneous/subcutaneous tumours of any histology; useful for palliation of bleeding or ulcerated melanoma and SCC nodules.
• Imiquimod and 5-FU (adjunctive/field therapy): Used for superficial BCC, AK field treatment and lentigo maligna (off-label) in anatomically challenging locations or as adjuncts post-surgery in immunosuppressed patients.
• Clinical trials: Multiple active trials evaluating novel targets including TIL (tumour-infiltrating lymphocyte) therapy for melanoma, LAG-3 inhibitors (relatlimab + nivolumab — approved for advanced melanoma, Opdualag), TIGIT inhibitors, personalised mRNA cancer vaccines (mRNA-4157/V940 + pembrolizumab — phase 3 KEYNOTE-942), and oncolytic virus therapy (T-VEC/talimogene laherparepvec for injectable melanoma metastases).
• Sun protection and primary prevention: Broad-spectrum SPF50+ sunscreen, UV-protective clothing and avoidance of peak UV hours reduce the risk of new primary skin cancers and recurrence. Nicotinamide 500 mg twice daily reduces new AK and NMSC development by 23% in high-risk patients (randomised trial, New Engl J Med 2015).
• Dermatoscopy surveillance programs: Total body photography combined with sequential dermoscopy for melanoma high-risk groups reduces unnecessary excisions and enables earlier detection of thin melanomas.